Research Original Investigation Monthly vs Treat-and-Extend Anti-VEGF Regimens for Macular Edema Invited Commentary The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing Short-term Similarities and Longer-term Questions Jennifer K. Sun, MD, MPH Therapy with anti–vascular endothelial growth factor (anti- cept and bevacizumab groups received statistically signifi- VEGF) agents has dramatically improved visual outcomes for cantly fewer injections on average (2 and 1.3 fewer injections, respectively), the clinical relevance of this point estimate of a patients with various retinal vascular diseases, including reti- nal vascular occlusion, diabetic macular edema, and neovas- 0.7-injection difference between groups over 6 months is un- cular age-related macular de- known. As might be expected in this short-duration, mod- generation. Landmark phase estly sized study, there were no differences in the safety pro- 3 randomized clinical trials file that were identified between the treatment groups. These Related article page 337 comparing anti-VEGF alter- results may be helpful to clinicians who are trying to choose natives have answered key questions regarding their compara- between treatment strategies by providing evidence that a TAE 1-3 tive effectiveness in these diseases. However, a remaining treatment strategy reduces the numbers of burdensome in- issue that faces physicians is
JAMA Ophthalmology – American Medical Association
Published: Apr 24, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera